Are Beta-Blockers Still Needed After a Heart Attack?
A deep dive into the REDUCE-AMI trial and what it means for patients recovering from a heart attack with preserved ejection fraction. The hosts examine why beta-blockers may no longer provide the same benefit in the modern PCI era, and where deprescribing fits in without abandoning patients who still need the drug.
Show Notes
- Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute ...: https://www.tctmd.com/news/another-beta-blocker-blow-reduce-ami-confirms-no-benefit-after-acute-mi
Chapter 1
The Golden Shield is Losing Its Shine
Dr. James Whitfield
So, I- I was looking at the discharge summaries from our clinic last week, Elena, and... and it hit me. Every single patient who came in after a myocardial infarction—a- a heart attack—was on a beta-blocker. Every. Single. One. It is just... it is an automatic reflex. We do it without even thinking.
Dr. Elena Rodriguez
Oh, absolutely. It is the... the "golden shield" of cardiology, right? But the thing is, James, that shield was forged in the... um, the 1970s and 80s. Back then, if you had a heart attack, we did not have emergency stents. We did not have modern antiplatelet drugs or high-intensity statins. Patients were left with these... these massive, permanent scars on their heart muscle.
Dr. James Whitfield
Right, exactly! The whole point of the beta-blocker back then was to... to decrease oxygen demand, to slow the heart down so this heavily damaged muscle wouldn't just fail. The trials back then proved it saved lives. There was very solid data showing that beta-blockers reduce the risk of mortality after a large MI.
Dr. Elena Rodriguez
Yes, after a *large* MI. But today? We have PCI—percutaneous coronary intervention. We get these patients into the cath lab immediately. We open the blocked artery in minutes. And the result? A- a huge percentage of patients walk out of the hospital with completely normal heart pumping capacity. Their, uh... their left ventricular ejection fraction is 50% or higher. No major scar. No heart failure.
Dr. James Whitfield
And yet... we still hand them the exact same "discharge cocktail" of five or six medications, including a heavy dose of beta-blockers. And then, two weeks later, they come to see me in clinic and they are... they are just miserable. They say, "Dr. Whitfield, I- I have this horrible brain fog. I can barely climb the stairs because I am so tired." Sometimes the younger men mention erectile dysfunction. It... it makes you ask: why are we putting them through this if their heart muscle is actually fine?
Dr. Elena Rodriguez
Exactly! That is the core tension. Are we treating the actual patient sitting in front of us, or are we just treating a historical habit? And that is precisely what the REDUCE-AMI trial, published in the New England Journal of Medicine in April 2024, set out to answer. Does this classic, protective therapy actually do anything for patients with a preserved ejection fraction in the modern era?
Chapter 2
The SWEDEHEART Revelation and the Future of Deprescribing
Dr. James Whitfield
Now, the way they ran this study is just... it is brilliant. They didn't do a traditional, ultra-expensive, highly curated clinical trial where patients are selected so carefully that they don't look like real-world patients. Instead, they did a pragmatic, registry-based randomized trial right inside Sweden's national SWEDEHEART registry. They enrolled 5,020 patients across 45 centers in Sweden, Estonia, and New Zealand.
Dr. Elena Rodriguez
Wait, five thousand and twenty? That is a massive sample size. And all of them had to have a preserved ejection fraction, right? What was the cutoff?
Dr. James Whitfield
Yes, an LVEF of 50% or higher, and they all underwent early coronary angiography. They randomized them into two groups: half got daily oral beta-blockers—mostly metoprolol or bisoprolol—and the other half got no beta-blocker at all. And they followed them for a median of... of 3.5 years.
Dr. Elena Rodriguez
Okay, so three and a half years of follow-up. What did the primary endpoint show? Did the beta-blocker group have fewer deaths or repeat heart attacks?
Dr. James Whitfield
No. None. The curves are... they are literally right on top of each other. The primary composite endpoint—which was death from any cause or a new heart attack—occurred in 7.9% of the beta-blocker group and... and 8.3% of the no-beta-blocker group. That gave a hazard ratio of 0.96. The p-value was 0.64. Statistically, it is a flat line of no difference.
Dr. Elena Rodriguez
Wow. A hazard ratio of 0.96. That is... that is absolutely striking. And what about secondary things like cardiovascular death or hospitalization for heart failure?
Dr. James Whitfield
Same thing. No difference at all. But here is the kicker, Elena. They did a pre-specified sub-study looking at patient-reported outcomes. The patients on beta-blockers reported... they actually reported slightly higher scores for depressive symptoms. So we are giving them a drug that makes them feel worse, with zero survival benefit.
Dr. Elena Rodriguez
It really highlights the... the cost of dogma, doesn't it? But, James, we need to be very, very careful about the boundaries here. This trial is a massive green light for what we call "deprescribing"—safely stopping or not starting beta-blockers in patients who have had an MI but have normal heart function and no other issues like atrial fibrillation. But... but who does this *not* apply to?
Dr. James Whitfield
Crucial point. If a patient has an ejection fraction *under* 50%, or if they have heart failure, beta-blockers are still an absolute, life-saving necessity. We are not throwing them out for everyone. We are just stopping the blind reflex for patients whose hearts have healed. It's time to... to tailor the medicine to the modern reality.
Dr. Elena Rodriguez
Mm, well said. It is all about precision, not habit. Alright, I think that is a wrap on this one. Good chatting, James.
Dr. James Whitfield
Sounds good, talk soon.